Description
Omaron Pharmacodynamics
Combined medicine with a pronounced antihypoxic, nootropic and vasodilator effect.
Piracetam activates metabolic processes in the brain by enhancing energy and protein metabolism, accelerating glucose utilization by cells and increasing their resistance to hypoxia; it improves inter-neuronal transmission in the central nervous system, improves regional blood flow in the ischemic area.
Cinnarizine is a selective blocker of “slow” calcium channels; it reduces influx of calcium ions into cells and decreases its content in plasma membrane depot, reduces arteriolar smooth muscle tone, reduces their response to biogenic vasoconstrictors (adrenaline, noradrenaline, dopamine, angiotensin II, vasopressin, serotonin). It has a vasodilator effect (especially on cerebral vessels, increasing the antihypoxic effect of piracetam), without having a significant effect on blood pressure. Shows moderate antihistamine activity, reduces the excitability of the vestibular apparatus, reduces the tone of the sympathetic nervous system. Increases elasticity of erythrocyte membranes and their ability to deform, reduces blood viscosity.
Indications
Diseases of the central nervous system, accompanied by a decrease in intellectual and mental functions.
As a part of complex therapy: insufficiency of cerebral circulation (atherosclerosis of cerebral blood vessels, rehabilitation period after ischemic and hemorrhagic stroke); post-toxic or post-traumatic encephalopathy; depression; psychorganic syndrome with predominating symptoms of asthenia and adynamia; vestibular disorders; Meniere’s syndrome; delayed intellectual development in children; prevention of migraine; prevention of kinetosis in adults and children.
Contraindications .
Hypersensitivity to the main and/or auxiliary components of the drug; severe hepatic insufficiency; severe renal insufficiency (creatinine clearance less than 20 ml/min); hemorrhagic stroke; Parkinsonism (incl. Parkinson’s disease); psychomotor agitation; Huntington’s disease; pregnancy; lactation; children under 5 years old; lactose intolerance, lactase deficiency, glucose-galactose malabsorption syndrome (drug contains lactose).
Dosage and administration
- Inside, during or after a meal.
- Adults: 1-2 tablets 3 times a day for 1-3 months, depending on the severity of the disease. Perhaps a refresher course of treatment – 2-3 times a year.
- Children over 5 years: 1-2 tablets 1-2 times a day. Do not use for more than 3 months.
- For prophylaxis of motion sickness: in adults – 1 tablet, in children over 5 years old – 1 /2 tablets 30 minutes before the trip, with repeated administration (if necessary) every 6-8 hours.
- Patients with impaired renal function: in chronic renal failure (creatinine clearance 20-80 ml/min) – 1 tablet 2 times a day.
